Back to top

Analyst Blog

Vivus Inc. (VVUS - Analyst Report) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. Results from the study revealed that the weight loss arising from treatment with Qsymia capsules CIV significantly reduced cholesterol, blood pressure and triglycerides levels in obese and overweight patients affected by one or more of these associated conditions.

Data from the study further revealed that significantly greater improvements were observed in patients who lost at least 10% of their initial weight following treatment with Qsymia. The primary endpoints of the study were percentage weight loss and the proportion of patients who underwent at least 5% weight loss after taking the drug. Data also revealed that treatment with Qsymia resulted in significantly greater dose-related mean percentage weight loss as opposed to placebo in the subgroups of patients suffering from dyslipidemia and hypertension.

We note that the drug is already available in the US. Qsymia was approved by the US Food and Drug Administration (FDA) in Jul 2012. The FDA cleared Qsymia as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI - 30 or more) or overweight (BMI - 27 or more) adults suffering from at least one weight-related co-morbid condition.

However the drug is yet to found favor with the European regulatory authorities. In Oct 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) did not recommend the approval of Qsiva (proposed trade name of the drug in Europe).

We remind investors that apart from Qsymia, another weight-loss drug, Arena Pharmaceuticals, Inc.’s (ARNA - Snapshot Report) Belviq, also received approval last year.

Vivus, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma stocks, such as Peregrine Pharmaceuticals, Inc. (PPHM - Snapshot Report) and Targacept, Inc. (TRGT - Snapshot Report) are much more favorably placed and carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%